细胞和基因治疗市场增长、规模、份额、趋势、关键参与者分析及 2031 年预测

  • Report Code : TIPRE00020854
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 232
Buy Now

预计到 2031 年,细胞和基因治疗市场规模将从 2023 年的 44.85 亿美元增至 280.5039 亿美元。预计 2023-2031 年期间市场复合年增长率将达到 25.8%。预测期内,人工智能 (AI) 和自动化技术的融合可能会为市场带来新趋势。

细胞和基因治疗市场分析

细胞和基因治疗获批数量的增加以及外包细胞和基因治疗制造的迅速普及是有利于细胞和基因治疗市场发展的因素。预计公司的战略举措也将在未来几年使市场受益。

细胞和基因治疗市场概况

生物技术的进步已导致人们采用针对各种适应症的个性化治疗。干细胞疗法被用于治疗癌症、神经系统疾病、遗传性疾病和其他慢性疾病。此外,细胞疗法的优势还包括靶向治疗、快速有效的恢复以及减少副作用。由于有食品和药物管理局 (FDA) 批准的产品,细胞疗法在世界各地被广泛采用。下面列出了近年来 FDA 批准的一些细胞和基因治疗产品:

  • 2024 年 4 月,FDA 批准辉瑞公司使用 BEQVEZ 治疗正在接受因子 IX (FIX) 预防治疗的中度至重度血友病 B 成人患者。FIX 缺乏会导致血友病 B(一种罕见的遗传性出血性疾病)患者比健康人出血更频繁、出血时间更长。这种疾病会阻碍正常的血液凝固。
  • 2023 年,FDA 批准了 Krystal Biotech, Inc. 生产的 VYJUVEK,用于治疗 6 个月及以上患有营养不良性大疱性表皮松解症且 VII 型胶原蛋白 α 1 链 (COL7A1) 基因出现突变的患者的伤口。

因此,细胞和基因治疗的批准数量不断增加,提高了制造能力,从而推动了细胞和基因治疗市场的增长。

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

细胞和基因治疗市场:

细胞和基因治疗市场
  • Cell and Gene Therapy Market
    复合年增长率(2023 - 2031)
    25.8%
  • 2023 年市场规模
    44.85 亿美元
  • 市场规模 2031年
    280.5039亿美元

市场动态

增长动力
  • 细胞和基因治疗获批数量的增加提高了制造能力,从而推动了细胞和基因治疗市场的增长
未来趋势
  • 人工智能与自动化技术的融合可能仍将是市场的主要趋势
机会
  • 预计主要参与者不断增加的战略举措将在预测期内为细胞和基因治疗市场创造巨大的增长机会

关键人物

  • 赛默飞世尔科技公司;
  • 默克集团;
  • 查尔斯河实验室;
  • 细胞和基因治疗弹射器;
  • 龙沙;
  • 药明康德;
  • Takara Bio Inc.;
  • 百时美施贵宝;
  • 富士胶片控股株式会社;
  • F.霍夫曼-罗氏有限公司;

区域概况

Cell and Gene Therapy Market
  • 北美
  • 欧洲
  • 亚太
  • 南美洲和中美洲
  • 中东和非洲

市场细分

Cell and Gene Therapy Market类型
  • 细胞疗法
  • 基因治疗
Cell and Gene Therapy Market服务
  • 工艺开发
  • cGMP 制造
  • 监管服务
  • 生物测定服务
Cell and Gene Therapy Market规模
  • 预商业化/研发制造
  • 商业规模制造
Cell and Gene Therapy Market服务提供商
  • 合同制造与生产组织
  • 首席营销官
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

细胞和基因治疗市场驱动因素和机遇

细胞和基因治疗制造外包迅速普及利好市场

细胞和基因疗法制造是一个复杂的过程,因此正确执行和监控操作至关重要。细胞和基因疗法制造商了解生物和过程工程的合格人员数量有限。此外,对于经验丰富的团队来说,管理使用手动和开放的制造方法进行首次临床试验的尝试以及构建更适合商业化的工艺可能具有挑战性。因此,这些制造商选择与合同开发和制造组织 (CDMO) 合作,以加速其临床研究和商业化进程。CDMO 在合同基础上为细胞和基因疗法公司提供产品开发、制造、临床试验和商业化服务支持。在与 CDMO 的合作下,细胞和基因疗法制造商可支持可扩展性、上市速度、无需管理费用即可获得技术专长以及提高成本效率。

企业创造市场机会的战略举措

许多从事细胞和基因治疗产品制造的公司专注于合作、扩张、协议、伙伴关系、新产品发布和其他战略发展。这些战略举措有助于他们提高销售额、扩大地理覆盖范围并提高满足庞大客户群的能力。以下提到了细胞和基因治疗市场的一些重要发展。

  • 2023 年 9 月,安捷伦科技公司与新加坡先进细胞治疗和研究中心 (ACTRIS) 签署了谅解备忘录 (MOU)。该协议旨在未来三年内促进细胞和基因治疗的发展。
  • 2022 年 3 月,Cellevolve Bio 与西雅图儿童治疗公司合作,开发和商业化用于儿童癌症的新型多重 CAR。通过此次合作,两家公司将专注于 BrainChild 研究计划(一套五种多重 CAR),用于治疗儿童中枢神经系统 (CNS) 恶性肿瘤。他们旨在利用西雅图儿童治疗工厂设施对新型 CAR 进行早期临床 GMP 研究。

通过合作和伙伴关系开展新业务以保持市场竞争力,有助于加速开发细胞和基因治疗制造服务的新平台。因此,预计主要参与者的这些战略举措将在预测期内为细胞和基因治疗市场创造巨大的增长机会。

细胞和基因治疗市场报告细分分析

有助于细胞和基因治疗市场分析的关键部分是产品类型、应用和最终用户。

  • 根据类型,细胞和基因治疗市场分为细胞治疗和基因治疗。细胞治疗领域在 2023 年占据了更大的市场份额。
  • 根据服务,市场分为工艺开发、cGMP 制造、监管服务和生物测定服务。工艺开发部分在 2023 年占据了最大的市场份额。
  • 按规模划分,市场分为预商用/研发制造和商业规模制造。2023 年,预商用/研发制造领域占据了更大的市场份额。
  • 根据服务提供商,市场分为 CDMO 和 CMO。2023 年,CDMO 部门占据了市场主导地位。
  • 根据最终用户,市场分为合同研究组织、制药和生物制药公司以及学术和研究机构。制药和生物制药公司部门在 2023 年占据了市场主导地位。

细胞和基因治疗市场份额按地区分析

细胞和基因治疗市场报告的地理范围主要分为五个区域:北美、亚太地区、欧洲、中东和非洲以及南美和中美洲。2023 年,北美占据了市场主导地位。北美细胞和基因治疗市场已在美国、加拿大和墨西哥的基础上进行了分析。美国细胞和基因治疗市场的增长归因于干细胞、基因和免疫疗法等细胞疗法的日益普及。遗传和细胞疾病的发病率不断上升,导致对细胞疗法的需求不断增加。根据美国基因与细胞治疗学会 (ASGCT) 的数据,目前有 3,633 种疗法正在研发中——55% 是基因,22% 是非转基因细胞,23% 是 RNA——从临床前到预注册。这些疗法针对各种疾病和病症,从癌症到遗传疾病再到神经系统疾病。截至 2024 年 2 月,美国已批准 19 种细胞和基因治疗产品用于治疗癌症、眼部疾病和罕见遗传性疾病。此外,该国正在经历越来越多的创新细胞疗法的初创企业。此外,政府的不断支持正在促进细胞疗法的发展,影响市场的发展。例如,美国基因与细胞治疗学会 (ASGCT) 是一个公共组织,为从事基因和细胞疗法的科学家、医生、专业人士和患者倡导者提供会员资格。ASGCT 旨在增强有关细胞和基因疗法临床应用的知识、教育和意识。

细胞和基因治疗市场报告范围

报告属性细节
2023 年的市场规模44.85 亿美元
2031 年市场规模280.5039亿美元
全球复合年增长率(2023 - 2031)25.8%
史料2021-2022
预测期2024-2031
涵盖的领域按类型
  • 细胞疗法
  • 基因治疗
按服务
  • 工艺开发
  • cGMP 制造
  • 监管服务
  • 生物测定服务
按规模
  • 预商业化/研发制造
  • 商业规模制造
按服务提供商
  • 合同制造与生产组织
  • 首席营销官
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  • 赛默飞世尔科技公司;
  • 默克集团;
  • 查尔斯河实验室;
  • 细胞和基因治疗弹射器;
  • 龙沙;
  • 药明康德;
  • Takara Bio Inc.;
  • 百时美施贵宝;
  • 富士胶片控股株式会社;
  • F.霍夫曼-罗氏有限公司;
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

细胞和基因治疗市场新闻和最新发展

细胞和基因治疗市场通过收集一级和二级研究后的定性和定量数据进行评估,其中包括重要的公司出版物、协会数据和数据库。以下列出了细胞和基因治疗市场的一些发展:

  • 韩国 CDMO 乐天生物制剂公司 (Lotte Biologics) 与默克集团 (Merck KGaA) 签署合作协议,重点是扩大生物制药生产和工艺开发。 (来源:乐天生物制剂公司网站,2024 年 6 月)
  • Catalent 推出了一项新的案例管理服务,该服务专门用于解决与安全及时向患者提供先进疗法相关的独特挑战,通过从项目开始到结束提供专业的供应链监督。细胞和基因疗法等先进治疗药物 (ATMP) 的供应链物流非常复杂,因为它们具有固有的敏感性、高价值以及每次剂量的某些患者特定复杂性。(来源:Catalent,公司网站,2023 年 1 月)

细胞和基因治疗市场报告覆盖范围和交付成果

“细胞和基因治疗市场规模和预测(2021-2031)”报告对以下领域进行了详细的市场分析:

  • 范围涵盖的所有主要细分市场的全球、区域和国家层面的细胞和基因治疗市场规模和预测
  • 细胞和基因治疗市场趋势以及市场动态,如驱动因素、限制因素和关键机遇
  • 详细的 PEST 和 SWOT 分析
  • 细胞和基因治疗市场分析涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新的市场发展。
  • 行业格局和竞争分析涵盖市场集中度、热图分析、知名参与者以及细胞和基因治疗市场的最新发展。
  • 详细的公司简介
  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which region dominated the cell and gene therapy market in 2023?

North America dominated the market in 2023.

What are the driving factors impacting the cell and gene therapy market?

Key factors that are driving the market are the increase in number of approvals of cell and gene therapies and rapid popularity of outsourcing cell and gene therapy manufacturing.

What are the significant future trends in the cell and gene therapy market?

Integration of artificial intelligence and automation technologies is likely to remain a key trend in the market.

Which are the leading players operating in the cell and gene therapy market?

Thermo Fisher Scientific, Inc.; Merck KGaA; Charles River Laboratories; Cell and Gene Therapy Catapult; Lonza; WuXi AppTec; Takara Bio Inc.; Bristol Myers Squibb; FUJIFILM Holdings Corporation; F. Hoffmann-La Roche Ltd.; and Catalent Biologics are among the key players operating in the market.

What would be the estimated value of the cell and gene therapy market by 2031?

The cell and gene therapy market value is estimated to reach US$ 28,050.39 million by 2031.

What is the expected CAGR of the cell and gene therapy market?

The cell and gene therapy market is anticipated to record a CAGR of 25.8% during 2023–2031.

Trends and growth analysis reports related to Life Sciences : READ MORE..   
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

The List of Companies - Cell and Gene Therapy Market

  1. Thermo Fisher Scientific, Inc.;
  2. Merck KGaA;
  3. Charles River Laboratories;
  4. Cell and Gene Therapy Catapult;
  5. Lonza; WuXi AppTec;
  6. Takara Bio Inc.;
  7. Bristol Myers Squibb;
  8. FUJIFILM Holdings Corporation;
  9. F. Hoffmann-La Roche Ltd.;
  10. Catalent Biologics
  11. Cell Therapies Pty Ltd

Buy Now  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.